FI20075971A0 - Komposition för behandling av steril inflammation - Google Patents

Komposition för behandling av steril inflammation

Info

Publication number
FI20075971A0
FI20075971A0 FI20075971A FI20075971A FI20075971A0 FI 20075971 A0 FI20075971 A0 FI 20075971A0 FI 20075971 A FI20075971 A FI 20075971A FI 20075971 A FI20075971 A FI 20075971A FI 20075971 A0 FI20075971 A0 FI 20075971A0
Authority
FI
Finland
Prior art keywords
sterile
composition
treating
pharmaceutical composition
treatment
Prior art date
Application number
FI20075971A
Other languages
English (en)
Finnish (fi)
Other versions
FI20075971A (sv
FI122450B (sv
Inventor
Thomas Tallberg
Original Assignee
Helsingin Bioimmunoterapialait
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingin Bioimmunoterapialait filed Critical Helsingin Bioimmunoterapialait
Publication of FI20075971A0 publication Critical patent/FI20075971A0/sv
Priority to FI20075971A priority Critical patent/FI122450B/sv
Priority to BRPI0821919-2A priority patent/BRPI0821919A2/pt
Priority to ES08868549T priority patent/ES2381690T3/es
Priority to NZ586496A priority patent/NZ586496A/en
Priority to DE08868549T priority patent/DE08868549T1/de
Priority to PL08868549T priority patent/PL2234611T3/pl
Priority to RU2010130889/15A priority patent/RU2462244C2/ru
Priority to JP2010540153A priority patent/JP5378406B2/ja
Priority to AT08868549T priority patent/ATE544450T1/de
Priority to CN2008801231858A priority patent/CN101917983B/zh
Priority to EP08868549A priority patent/EP2234611B1/en
Priority to NZ597976A priority patent/NZ597976A/xx
Priority to DK08868549.0T priority patent/DK2234611T3/da
Priority to KR1020107016810A priority patent/KR20100103856A/ko
Priority to NZ597977A priority patent/NZ597977A/xx
Priority to AU2008345508A priority patent/AU2008345508B2/en
Priority to US12/810,150 priority patent/US20100291235A1/en
Priority to PCT/FI2008/050750 priority patent/WO2009083643A2/en
Publication of FI20075971A publication Critical patent/FI20075971A/sv
Priority to IL206596A priority patent/IL206596A0/en
Priority to HK10110064.8A priority patent/HK1143539A1/xx
Application granted granted Critical
Publication of FI122450B publication Critical patent/FI122450B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FI20075971A 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation FI122450B (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FI20075971A FI122450B (sv) 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation
EP08868549A EP2234611B1 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
DK08868549.0T DK2234611T3 (da) 2007-12-28 2008-12-17 Sammensætning til behandling af steril inflammation
NZ586496A NZ586496A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
DE08868549T DE08868549T1 (de) 2007-12-28 2008-12-17 Zusammensetzung zur behandlung steriler entzündungen
PL08868549T PL2234611T3 (pl) 2007-12-28 2008-12-17 Kompozycja do leczenia jałowego zapalenia
RU2010130889/15A RU2462244C2 (ru) 2007-12-28 2008-12-17 Композиция для лечения неинфекционного воспаления
JP2010540153A JP5378406B2 (ja) 2007-12-28 2008-12-17 無菌性炎症の治療用組成物
AT08868549T ATE544450T1 (de) 2007-12-28 2008-12-17 Zusammensetzung zur behandlung steriler entzündungen
CN2008801231858A CN101917983B (zh) 2007-12-28 2008-12-17 用于治疗无菌性炎症的组合物
BRPI0821919-2A BRPI0821919A2 (pt) 2007-12-28 2008-12-17 Composição para tratamento de inflamação não-infecciosa
NZ597976A NZ597976A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
ES08868549T ES2381690T3 (es) 2007-12-28 2008-12-17 Composición para tratar inflamación estéril
KR1020107016810A KR20100103856A (ko) 2007-12-28 2008-12-17 무균성 염증을 치료하기 위한 조성물
NZ597977A NZ597977A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
AU2008345508A AU2008345508B2 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
US12/810,150 US20100291235A1 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
PCT/FI2008/050750 WO2009083643A2 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
IL206596A IL206596A0 (en) 2007-12-28 2010-06-24 Composition for treating sterile inflammation
HK10110064.8A HK1143539A1 (en) 2007-12-28 2010-10-26 Composition for treating sterile inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20075971 2007-12-28
FI20075971A FI122450B (sv) 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation

Publications (3)

Publication Number Publication Date
FI20075971A0 true FI20075971A0 (sv) 2007-12-28
FI20075971A FI20075971A (sv) 2009-06-29
FI122450B FI122450B (sv) 2012-01-31

Family

ID=38951666

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075971A FI122450B (sv) 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation

Country Status (18)

Country Link
US (1) US20100291235A1 (sv)
EP (1) EP2234611B1 (sv)
JP (1) JP5378406B2 (sv)
KR (1) KR20100103856A (sv)
CN (1) CN101917983B (sv)
AT (1) ATE544450T1 (sv)
AU (1) AU2008345508B2 (sv)
BR (1) BRPI0821919A2 (sv)
DE (1) DE08868549T1 (sv)
DK (1) DK2234611T3 (sv)
ES (1) ES2381690T3 (sv)
FI (1) FI122450B (sv)
HK (1) HK1143539A1 (sv)
IL (1) IL206596A0 (sv)
NZ (3) NZ597976A (sv)
PL (1) PL2234611T3 (sv)
RU (1) RU2462244C2 (sv)
WO (1) WO2009083643A2 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142736A1 (en) * 2010-08-18 2013-06-06 Colgatge-Palmolive Company Oral care product and methods of use and manufacture thereof
FI123756B (sv) * 2010-09-21 2013-10-31 Neurofood Ab Oy Förbättrat näringstillskott för behandling och förebyggande av cancer
JP5837315B2 (ja) * 2011-03-25 2015-12-24 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
RU2156087C1 (ru) * 1999-11-25 2000-09-20 Товарищество с ограниченной ответственностью Фирма "Электронная медицина" Биологически активная добавка
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
ES2342461T3 (es) * 2003-10-17 2010-07-07 Oy Neurofood Ab Agente de estroncio no radiactivo para tratar el cancer.
FI121915B (sv) * 2004-02-06 2011-06-15 Neurofood Ab Oy Komposition för behandling av psoriasis
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
RU2308199C2 (ru) * 2005-05-13 2007-10-20 Закрытое акционерное общество "Компания "Нутритек" (ЗАО "Компания "Нутритек") Продукт энтерального питания "нутриэн гепа"

Also Published As

Publication number Publication date
EP2234611B1 (en) 2012-02-08
KR20100103856A (ko) 2010-09-28
AU2008345508A1 (en) 2009-07-09
NZ597977A (en) 2012-08-31
JP5378406B2 (ja) 2013-12-25
EP2234611A2 (en) 2010-10-06
US20100291235A1 (en) 2010-11-18
RU2462244C2 (ru) 2012-09-27
CN101917983B (zh) 2013-08-21
DE08868549T1 (de) 2011-03-17
FI20075971A (sv) 2009-06-29
JP2011507937A (ja) 2011-03-10
FI122450B (sv) 2012-01-31
CN101917983A (zh) 2010-12-15
WO2009083643A2 (en) 2009-07-09
WO2009083643A3 (en) 2009-10-29
ES2381690T3 (es) 2012-05-30
HK1143539A1 (en) 2011-01-07
RU2010130889A (ru) 2012-02-10
AU2008345508B2 (en) 2013-11-14
PL2234611T3 (pl) 2012-07-31
BRPI0821919A2 (pt) 2015-06-16
ATE544450T1 (de) 2012-02-15
IL206596A0 (en) 2010-12-30
DK2234611T3 (da) 2012-05-07
NZ586496A (en) 2012-03-30
NZ597976A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
AU2016216625A1 (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
WO2007006307A3 (en) Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
WO2006097337A3 (en) 11β-HYDROXYSTEROID DEHYDROGENASES
WO2006003488A3 (en) Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ATE549338T1 (de) Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
FI20075971A0 (sv) Komposition för behandling av steril inflammation
GEP20125438B (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
NO20063937L (no) Sammensetning omfattende L-serin, L-isoleucin, folsyre og sporelementer for behandling av psoriasis
MX2022014924A (es) Moduladores de il-17a.
MX2022014925A (es) Moduladores de il-17a.
ZA200703992B (en) 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
Sahu et al. Cow urine-Therapeutic value
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
ATE489994T1 (de) Zusammensetzungen zur behandlung von luminalen entzündlichen erkrankungen
CN117479948A (zh) 用于预防或治疗神经源性炎症的多离子复合物
Kannan Nano microbe zapper (NMZ): a novel eco-safe nanoparticle mediated antimicrobial killer
Wound Healing and Management Node Group Evidence summary: Wound management: Doxycycline for chronic wounds

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: OY NEUROFOOD AB

Free format text: OY NEUROFOOD AB

FG Patent granted

Ref document number: 122450

Country of ref document: FI

MM Patent lapsed